| Literature DB >> 26195069 |
Wenjing Pang1, Jiaojiao Su2,3, Yalei Wang2, Hui Feng2, Xin Dai1, Yaozong Yuan1, Xi Chen4, Weiyan Yao1.
Abstract
Cancer-associated fibroblasts (CAF) are a major constituent of the pancreatic cancer microenvironment and that the meaning is as intended. Pancreatic cancer cells can induce normal fibroblasts to convert into CAF and, reciprocally, CAF promote tumor invasions and proliferations. The mechanism of the conversion from normal fibroblasts (NF) to CAF remains unclear. MicroRNA are short non-coding RNA involved in the post-transcription gene regulation, which have been defined as an imperative controller in tumor invasions, proliferations and colony formations. Microvesicles (MV) have been proved to be an important mediator of intercellular communication and can selectively transport secreted microRNA from a donor cell into a recipient cell. In this study, we isolated primary pancreatic fibroblasts from wild type C57 mice and co-cultured them with pancreatic cancer cell lines, BxPC-3 and SW1990, and observed the conversion from NF to CAF, or at least CAF-like cells. This phenomenon could also be replicated in primary fibroblasts treated with MV separated from a cancer cell media. We identified that miR-155 was upregulated in PaC-derived MV and we confirmed that normal fibroblasts could convert into CAF after MV containing miR-155 had been taken up. TP53INP1 is a target of miR-155 in fibroblasts and a downregulation of TP53INP1 protein levels could contribute to the fibroblasts' activation. These results indicated that pancreatic cancer cells might reprogram normal adjacent fibroblasts into CAF by means of secreted MV containing miR-155. Targeting the circulating microRNA might be a potential therapy for malignant tumors.Entities:
Keywords: Cancer-associated fibroblast; microRNA; microvesicle; pancreatic neoplasm; tumor microenvironment
Mesh:
Substances:
Year: 2015 PMID: 26195069 PMCID: PMC4638007 DOI: 10.1111/cas.12747
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
Figure 1Normal fibroblasts (NF) converted into cancer-associated fibroblasts (CAF) after being co-cultivated with pancreatic cancer (PaC) cells. (a, b) Western blot analysis of α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) protein levels in NF co-cultivated with PaC cells. (c, d) Edu proliferation assay analysis in NF and NF co-cultivated with PaC cells. (e) Quantitative RT-PCR analysis of miRNA expression levels in NF and NF co-cultivated with PaC cells. (f, g) Cell migration analysis in NF and NF co-cultivated with PaC cells. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2Normal fibroblasts (NF) converted into cancer-associated fibroblasts (CAF) after being treated with pancreatic cancer (PaC)-derived microvesicles (MV). (a, b) Western blot analysis of α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) protein levels in NF treated with PaC-derived MV. (c, d) Edu proliferation assay analysis in NF and NF treated with PaC-derived MV. (e) Quantitative RT-PCR analysis of miRNA expression levels in NF and NF treated with PaC-derived MV. (f, g) Cell migration analysis in NF and NF treated with PaC-derived MV. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3Unapparent conversion from normal fibroblasts (NF) to cancer-associated fibroblasts (CAF) if treated with miR-155-deficient microvesicles (MV). (a, b) Western blot analysis of α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) protein levels in NF and NF treated with miR-155-deficient BxPC-3-derived MV and controls. (c, d) Western blot analysis of α-SMA and FAP protein levels in NF treated with miR-155-deficient SW1990-derived MV and controls. (e, f) Edu proliferation assay analysis of NF and NF treated with miR-155-deficient BxPC-3-derived MV and controls. (g, h) Edu proliferation assay analysis of NF and NF treated with miR-155-deficient SW1990-derived MV and controls. **P < 0.01; ***P < 0.001.
Figure 4Alteration of TP53INP1 protein levels in normal fibroblasts (NF) to cancer-associated fibroblast (CAF) conversion. (a, b) Western blot analysis of TP53INP1 protein levels in NF co-cultivated with pancreatic cancer (PaC) cells. (a, b) Western blot analysis of α-smooth muscle actin (α-SMA) and fibroblast cells. (c, d) Western blot analysis of TP53INP1 protein levels in NF treated with PaC-derived microvesicles (MV). (e, f) Western blot analysis of TP53INP1 protein levels in NF treated with miR-155-deficient BxPC-3-derived MV and controls. (g, h) Western blot analysis of TP53INP1 protein levels in NF treated with miR-155-deficient SW1990-derived MV and controls. *P < 0.05; ***P < 0.001.